首页 > 最新文献

Expert Opinion on Drug Safety最新文献

英文 中文
Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database. 利用 FDA 不良事件报告系统数据库评估伊伐布雷定在真实世界中的安全性。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-04 DOI: 10.1080/14740338.2024.2412220
Fajun Li, Xin Su, Fuliang Cai

Background: Ivabradine is primarily indicated for patients with sinus rhythm and a heart rate ≥ 75 beats/min, who have NYHA class II-IV chronic heart failure with systolic dysfunction. There is currently a lack of large-scale, real-world studies concerning its drug adverse reactions.

Research design & methods: This research assesses the side effects of ivabradine by analyzing reports of adverse events (AEs) from the FDA's Adverse Event Reporting System (FAERS) database. To evaluate the importance of these AEs, four sequential analytic strategies were utilized.

Results: In total, 2,701 ivabradine-related AE reports were identified in the FAERS database. We identified 26 ivabradine-induced AEs, each with more than 20 reports, including some significant AEs not mentioned on the product label. The timing of AEs was also analyzed, with the majority of AEs occurring within the first month of ivabradine use. Gender-specific analysis indicates that female have a higher risk of AEs, such as off-label use, tachycardia, drug effectiveness for unapproved indications, and rash compared to male.

Conclusion: This study provides important information for maximizing the usage of ivabradine, increasing its efficacy, and reducing any possible negative effects. The actual clinical use of the medication will be greatly aided by this knowledge.

背景:伊伐布雷定主要适用于窦性心律、心率≥75次/分、NYHA分级为II-IV级、伴有收缩功能障碍的慢性心力衰竭患者。目前还缺乏有关其药物不良反应的大规模真实世界研究:本研究通过分析美国食品及药物管理局不良事件报告系统(FAERS)数据库中的不良事件(AEs)报告,评估伊伐布雷定的副作用。为了评估这些 AEs 的重要性,研究采用了四种连续分析策略:结果:FAERS 数据库中共发现 2,701 份与伊伐布雷定相关的 AE 报告。我们发现了 26 种伊伐布雷定诱发的 AE,每种都有 20 多份报告,其中包括一些产品标签上未提及的重要 AE。我们还分析了发生 AE 的时间,大多数 AE 发生在使用伊伐布雷定的第一个月内。性别特异性分析表明,与男性相比,女性发生标示外使用、心动过速、药物在未经批准的适应症中的有效性和皮疹等不良反应的风险更高:这项研究为最大限度地使用伊伐布雷定、提高其疗效和减少可能出现的负面影响提供了重要信息。这些知识将大大有助于该药物的实际临床应用。
{"title":"Assessment of safety profile of ivabradine in real-world scenario using FDA adverse event reporting system database.","authors":"Fajun Li, Xin Su, Fuliang Cai","doi":"10.1080/14740338.2024.2412220","DOIUrl":"10.1080/14740338.2024.2412220","url":null,"abstract":"<p><strong>Background: </strong>Ivabradine is primarily indicated for patients with sinus rhythm and a heart rate ≥ 75 beats/min, who have NYHA class II-IV chronic heart failure with systolic dysfunction. There is currently a lack of large-scale, real-world studies concerning its drug adverse reactions.</p><p><strong>Research design & methods: </strong>This research assesses the side effects of ivabradine by analyzing reports of adverse events (AEs) from the FDA's Adverse Event Reporting System (FAERS) database. To evaluate the importance of these AEs, four sequential analytic strategies were utilized.</p><p><strong>Results: </strong>In total, 2,701 ivabradine-related AE reports were identified in the FAERS database. We identified 26 ivabradine-induced AEs, each with more than 20 reports, including some significant AEs not mentioned on the product label. The timing of AEs was also analyzed, with the majority of AEs occurring within the first month of ivabradine use. Gender-specific analysis indicates that female have a higher risk of AEs, such as off-label use, tachycardia, drug effectiveness for unapproved indications, and rash compared to male.</p><p><strong>Conclusion: </strong>This study provides important information for maximizing the usage of ivabradine, increasing its efficacy, and reducing any possible negative effects. The actual clinical use of the medication will be greatly aided by this knowledge.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-7"},"PeriodicalIF":3.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study. 探索 SGLT-2 抑制剂与 FAERS 中的肌肉疏松症:一项上市后监测研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-04 DOI: 10.1080/14740338.2024.2412234
Zheng Kuai, Yangli Ye, Xiaoyi Zhang, Lihong Gao, Guowen Tang, Jie Yuan

Background: The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear.

Research design and methods: Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs.

Results: The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use.

Conclusions: Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.

背景:钠依赖性葡萄糖转运体2抑制剂(SGLT-2i)与体重减轻有关,但体重减轻的成分仍不清楚:采用报告几率比(ROR)、报告比例比(PRR)、贝叶斯置信度传播神经网络(BCPN)和多项目伽玛泊松收缩器(MGPS)算法等比例失调分析方法,量化与SGLT-2i相关的肌肉骨骼和结缔组织疾病AEs信号:结果:在报告期内,共检索到 3,206 例与肌肉骨骼和结缔组织疾病相关的 AEs。其中包括1,061例Canagliflozin、1,052例Dapagliflozin、1,074例Empagliflozin和19例Ertugliflozin。保留了 15 个比例严重失调的首选术语 (PT)。Ertugliflozin 未报告与肌肉骨骼和结缔组织系统相关的 AE 信号。我们发现使用 Canagliflozin 有发生肌肉坏死的风险,使用 Dapagliflozin 有发生肌少症的风险,使用 Dapagliflozin 和 Empagliflozin 处方有发生肌肉萎缩的可能。大多数病例发生在开始使用SGLT-2i后的第一个月内,AEs可持续到使用360天以后:我们的研究发现了与 SGLT-2 抑制剂相关的肌肉骨骼和结缔组织疾病相关的潜在新 AE 信号。
{"title":"Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study.","authors":"Zheng Kuai, Yangli Ye, Xiaoyi Zhang, Lihong Gao, Guowen Tang, Jie Yuan","doi":"10.1080/14740338.2024.2412234","DOIUrl":"10.1080/14740338.2024.2412234","url":null,"abstract":"<p><strong>Background: </strong>The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear.</p><p><strong>Research design and methods: </strong>Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs.</p><p><strong>Results: </strong>The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use.</p><p><strong>Conclusions: </strong>Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-8"},"PeriodicalIF":3.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system. 与转移性结直肠癌患者使用氟尿嘧啶相关的药物不良事件:基于美国食品药物管理局不良事件报告系统的真实世界药物警戒研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI: 10.1080/14740338.2024.2380513
Ruiqi Zhao, Mengyao Han, Sen Lin, Zhimei Lin, Mengjiao Yu, Bei Zhang, Lanyue Ma, Danfei Li, Lisheng Peng

Background: Fluorouracil (5-FU) is widely used to treat metastatic colorectal cancer (mCRC), but real-world safety data is limited. Our study aimed to evaluate 5-FU's safety profile in a large mCRC population using the FAERS database.

Research design and methods: We conducted disproportionality analyses to identify adverse drug events associated with 5-FU use in mCRC patients from 2004 to 2023. Subgroup analyses, gender difference analyses, and logistic regression were also performed.

Results: We identified 1,458 reports with 5-FU as the primary suspected drug, with males accounting for 48.8% of reports. Gastrointestinal disorders were the most common adverse event (864 cases), while pregnancy-related conditions showed the strongest signal intensity (ROR = 2.97). We found 19 preferred terms with positive signals, including ischemic hepatitis (ROR = 59.32), blood iron increased (ROR = 59.32), and stress cardiomyopathy (ROR = 51.94). Males were more susceptible to weight loss and skin toxicity. Most adverse events occurred within the first month of 5-FU administration.

Conclusion: Our study provides a comprehensive analysis of 5-FU's safety profile in mCRC patients, helping healthcare professionals mitigate risks in clinical practice.

背景:氟尿嘧啶(5-FU)被广泛用于治疗转移性结直肠癌(mCRC),但真实世界的安全性数据有限。我们的研究旨在利用 FAERS 数据库评估 5-FU 在大量 mCRC 患者中的安全性:我们进行了比例失调分析,以确定 2004 年至 2023 年间在 mCRC 患者中使用 5-FU 的相关药物不良事件。我们还进行了亚组分析、性别差异分析和逻辑回归:结果:我们发现了 1458 份以 5-FU 为主要可疑药物的报告,其中男性占 48.8%。胃肠功能紊乱是最常见的不良事件(864 例),而与妊娠相关的情况显示出最强的信号强度(ROR = 2.97)。我们发现 19 个首选术语具有阳性信号,包括缺血性肝炎(ROR = 59.32)、血铁增加(ROR = 59.32)和应激性心肌病(ROR = 51.94)。男性更容易出现体重减轻和皮肤中毒。大多数不良反应发生在服用 5-FU 的第一个月内:我们的研究全面分析了5-FU在mCRC患者中的安全性,有助于医护人员在临床实践中降低风险。
{"title":"Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system.","authors":"Ruiqi Zhao, Mengyao Han, Sen Lin, Zhimei Lin, Mengjiao Yu, Bei Zhang, Lanyue Ma, Danfei Li, Lisheng Peng","doi":"10.1080/14740338.2024.2380513","DOIUrl":"10.1080/14740338.2024.2380513","url":null,"abstract":"<p><strong>Background: </strong>Fluorouracil (5-FU) is widely used to treat metastatic colorectal cancer (mCRC), but real-world safety data is limited. Our study aimed to evaluate 5-FU's safety profile in a large mCRC population using the FAERS database.</p><p><strong>Research design and methods: </strong>We conducted disproportionality analyses to identify adverse drug events associated with 5-FU use in mCRC patients from 2004 to 2023. Subgroup analyses, gender difference analyses, and logistic regression were also performed.</p><p><strong>Results: </strong>We identified 1,458 reports with 5-FU as the primary suspected drug, with males accounting for 48.8% of reports. Gastrointestinal disorders were the most common adverse event (864 cases), while pregnancy-related conditions showed the strongest signal intensity (ROR = 2.97). We found 19 preferred terms with positive signals, including ischemic hepatitis (ROR = 59.32), blood iron increased (ROR = 59.32), and stress cardiomyopathy (ROR = 51.94). Males were more susceptible to weight loss and skin toxicity. Most adverse events occurred within the first month of 5-FU administration.</p><p><strong>Conclusion: </strong>Our study provides a comprehensive analysis of 5-FU's safety profile in mCRC patients, helping healthcare professionals mitigate risks in clinical practice.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1295-1307"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches. 南非的疫苗药物警戒:当前方法的成功与局限。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-09-24 DOI: 10.1080/14740338.2024.2387322
J Peter, A Takalani, J C Meyer, B Semete-Makokotlela, S Collie, I Seocharan, A Goga, N Garrett, L Gail-Bekker, G Gray

Introduction: Despite the public health success of vaccination, there is an ongoing need to build public confidence in vaccines and improve systems to monitor safety while maintaining data security and patient privacy. African countries face multiple challenges in establishing systems for vaccine pharmacovigilance as was demonstrated during COVID-19 mass vaccination. We provide a framework for the development of pharmacovigilance using the COVID-19 vaccination rollout as an exemplar.

Areas covered: We describe the pre-COVID-19 vaccine pharmacovigilance systems in Southern Africa and propose improvements based on our experience of COVID-19 vaccine rollout in South Africa where we implemented systems to evaluate real-world safety and effectiveness of COVID-19 vaccinations. By conducting a PubMed review of the literature on pharmacovigilance with a focus on Africa and from guidance emanating from the World Health Organization (WHO), we evaluate challenges and opportunities to improve pharmacovigilance in our setting.

Expert opinion: There are ongoing efforts to improve pharmacovigilance on the African continent with improved coordination at a national level with the support of the WHO, the national regulatory authorities, and national departments of health. COVID-19 vaccine rollout provided an opportunity to improve pharmacovigilance by integrating national vaccine platforms with active and passive surveillance including hospital and death registries.

导言:尽管疫苗接种在公共卫生方面取得了成功,但仍需不断建立公众对疫苗的信心,并在维护数据安全和患者隐私的同时改进安全监控系统。非洲国家在建立疫苗药物警戒系统方面面临着多重挑战,这在 COVID-19 大规模疫苗接种过程中得到了证明。我们以 COVID-19 疫苗接种为例,为药物警戒的发展提供了一个框架:我们描述了南部非洲 COVID-19 疫苗接种前的药物警戒系统,并根据我们在南非推广 COVID-19 疫苗的经验提出了改进建议,我们在南非实施了评估 COVID-19 疫苗接种的实际安全性和有效性的系统。我们在南非实施了 COVID-19 疫苗接种真实世界安全性和有效性评估系统,并根据我们的经验提出了改进建议。通过对有关药物警戒的文献进行文献综述,重点关注非洲和世界卫生组织 (WHO) 的指导意见,我们评估了在我们的环境中改进药物警戒所面临的挑战和机遇:在世界卫生组织、国家监管机构和国家卫生部门的支持下,非洲大陆正在努力改善国家层面的药物警戒协调。COVID-19疫苗的推出为通过整合国家疫苗平台与主动和被动监测(包括医院和死亡登记)来改善药物警戒提供了机会。
{"title":"Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches.","authors":"J Peter, A Takalani, J C Meyer, B Semete-Makokotlela, S Collie, I Seocharan, A Goga, N Garrett, L Gail-Bekker, G Gray","doi":"10.1080/14740338.2024.2387322","DOIUrl":"10.1080/14740338.2024.2387322","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the public health success of vaccination, there is an ongoing need to build public confidence in vaccines and improve systems to monitor safety while maintaining data security and patient privacy. African countries face multiple challenges in establishing systems for vaccine pharmacovigilance as was demonstrated during COVID-19 mass vaccination. We provide a framework for the development of pharmacovigilance using the COVID-19 vaccination rollout as an exemplar.</p><p><strong>Areas covered: </strong>We describe the pre-COVID-19 vaccine pharmacovigilance systems in Southern Africa and propose improvements based on our experience of COVID-19 vaccine rollout in South Africa where we implemented systems to evaluate real-world safety and effectiveness of COVID-19 vaccinations. By conducting a PubMed review of the literature on pharmacovigilance with a focus on Africa and from guidance emanating from the World Health Organization (WHO), we evaluate challenges and opportunities to improve pharmacovigilance in our setting.</p><p><strong>Expert opinion: </strong>There are ongoing efforts to improve pharmacovigilance on the African continent with improved coordination at a national level with the support of the WHO, the national regulatory authorities, and national departments of health. COVID-19 vaccine rollout provided an opportunity to improve pharmacovigilance by integrating national vaccine platforms with active and passive surveillance including hospital and death registries.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1215-1225"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS. 与抗 MRSA 药物相关的血液学不良事件:基于 FAERS 的真实世界分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-01-25 DOI: 10.1080/14740338.2024.2309225
Xiuheng Yu, Xiaodan Zhou, Min Li, Yu Zhao

This study investigated the patterns of hematological adverse events related to daptomycin (DAP), tigecycline (TIG), vancomycin (VAN) and linezolid (LIN) in the FDA Adverse Event Reporting System (FAERS). Adverse event associations were analyzed through calculating reporting odds ratio (ROR), proportional reporting ratio (PRR), multiple gamma Poisson shrinkage (MGPS), and Bayesian confidence propagation neural network (BCPNN). A comprehensive descriptive analysis was also conducted considering factors such as age, gender, daily dose, cumulative dose, and time to onset. The leading hematologic adverse events were eosinophilia for daptomycin, coagulation abnormalities and thrombocytopenia for tigecycline, thrombocytopenia, neutropenia, and anemia for linezolid, and thrombocytopenia, eosinophilia, and neutropenia for vancomycin. Most of the affected patients were over 55 years old. Daily doses for the tigecycline and daptomycin groups exceeded the standard daily dose. The times to onset were 14.00 days for daptomycin (interquartile range [IQR], 4.00-21.00), 6.00 days for tigecycline (IQR, 2.00-9.00), 10.00 days for linezolid (IQR, 4.00-16.5), and 10.00 days for vancomycin (IQR,5.00-20.00). It is essential to intensify early monitoring and identification of these adverse events, especially in the context of off-label dosages and for elderly patients and individuals taking medication for over one week.

本研究调查了 FDA 不良事件报告系统 (FAERS) 中与达托霉素 (DAP)、替加环素 (TIG)、万古霉素 (VAN) 和利奈唑胺 (LIN) 相关的血液学不良事件的模式。通过计算报告几率比(ROR)、比例报告比(PRR)、多伽马泊松收缩(MGPS)和贝叶斯置信传播神经网络(BCPN)分析了不良事件的关联性。考虑到年龄、性别、日剂量、累积剂量和发病时间等因素,还进行了综合描述性分析。主要的血液学不良事件是:达托霉素引起嗜酸性粒细胞增多;替加环素引起凝血异常和血小板减少;利奈唑胺引起血小板减少、中性粒细胞减少和贫血;万古霉素引起血小板减少、嗜酸性粒细胞增多和中性粒细胞减少。大多数患者年龄超过 55 岁。替加环素和达托霉素组的日剂量超过了标准日剂量。达托霉素的发病时间为 14.00 天(四分位数间距 [IQR],4.00-21.00),替加环素为 6.00 天(IQR,2.00-9.00),利奈唑胺为 10.00 天(IQR,4.00-16.5),万古霉素为 10.00 天(IQR,5.00-20.00)。必须加强对这些不良事件的早期监测和识别,尤其是在标签外剂量、老年患者和服药超过一周的患者中。
{"title":"Hematological adverse events associated with anti-MRSA agents: a real-world analysis based on FAERS.","authors":"Xiuheng Yu, Xiaodan Zhou, Min Li, Yu Zhao","doi":"10.1080/14740338.2024.2309225","DOIUrl":"10.1080/14740338.2024.2309225","url":null,"abstract":"<p><p>This study investigated the patterns of hematological adverse events related to daptomycin (DAP), tigecycline (TIG), vancomycin (VAN) and linezolid (LIN) in the FDA Adverse Event Reporting System (FAERS). Adverse event associations were analyzed through calculating reporting odds ratio (ROR), proportional reporting ratio (PRR), multiple gamma Poisson shrinkage (MGPS), and Bayesian confidence propagation neural network (BCPNN). A comprehensive descriptive analysis was also conducted considering factors such as age, gender, daily dose, cumulative dose, and time to onset. The leading hematologic adverse events were eosinophilia for daptomycin, coagulation abnormalities and thrombocytopenia for tigecycline, thrombocytopenia, neutropenia, and anemia for linezolid, and thrombocytopenia, eosinophilia, and neutropenia for vancomycin. Most of the affected patients were over 55 years old. Daily doses for the tigecycline and daptomycin groups exceeded the standard daily dose. The times to onset were 14.00 days for daptomycin (interquartile range [IQR], 4.00-21.00), 6.00 days for tigecycline (IQR, 2.00-9.00), 10.00 days for linezolid (IQR, 4.00-16.5), and 10.00 days for vancomycin (IQR,5.00-20.00). It is essential to intensify early monitoring and identification of these adverse events, especially in the context of off-label dosages and for elderly patients and individuals taking medication for over one week.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1283-1293"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139511972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review. 与使用抗抑郁药和抗精神病药相关的体重增加的风险因素、预防和治疗:最新临床综述。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-09-23 DOI: 10.1080/14740338.2024.2396396
Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll

Introduction: People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.

Areas covered: We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.

Expert opinion: To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.

导言严重精神疾病患者的心脏代谢健康状况较差。常用的抗抑郁药和抗精神病药经常会导致体重增加,这可能会进一步导致不良的心血管后果:我们检索了截至 2023 年 4 月的 MEDLINE,以了解与抗抑郁药/抗精神病药相关的体重增加的风险因素、预防和治疗策略方面的综述、(网络)荟萃分析、试验和队列研究。我们制定了 10 项临床建议:为预防、管理和治疗与抗抑郁药/精神药物相关的体重增加,我们建议 i) 在治疗前评估肥胖的风险因素;ii) 在基线和随访期间定期监测代谢健康状况;iii) 根据患者的偏好提供生活方式干预,包括定期锻炼和健康饮食,以优化患者的积极性;iv) 考虑对轻中度抑郁症和焦虑症患者进行一线心理治疗;v) 根据药物和患者体重增加的风险选择药物、viii) 尽可能改用对体重增加影响较小的抗精神病药物/抗抑郁药物; ix) 将早期体重增加作为进一步体重增加的预测指标,以确定干预/转换方案的时机、以及 x) 考虑在抗精神病药物中添加二甲双胍或胰高血糖素样肽-1 受体激动剂,或托吡酯(因可能对认知产生不良影响而属于二线用药),或阿立哌唑替代氯氮平或奥氮平。
{"title":"Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review.","authors":"Marco Solmi, Alessandro Miola, Federico Capone, Simone Pallottino, Mikkel Højlund, Joseph Firth, Dan Siskind, Richard I G Holt, Olivier Corbeil, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, René Ernst Nielsen, Merete Nordentoft, Paolo Fusar-Poli, Catharina A Hartman, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Heidi Taipale, Christoph U Correll","doi":"10.1080/14740338.2024.2396396","DOIUrl":"10.1080/14740338.2024.2396396","url":null,"abstract":"<p><strong>Introduction: </strong>People with severe mental illness have poor cardiometabolic health. Commonly used antidepressants and antipsychotics frequently lead to weight gain, which may further contribute to adverse cardiovascular outcomes.</p><p><strong>Areas covered: </strong>We searched MEDLINE up to April 2023 for umbrella reviews, (network-)meta-analyses, trials and cohort studies on risk factors, prevention and treatment strategies of weight gain associated with antidepressants/antipsychotics. We developed 10 clinical recommendations.</p><p><strong>Expert opinion: </strong>To prevent, manage, and treat antidepressant/antipsychotic-related weight gain, we recommend i) assessing risk factors for obesity before treatment, ii) monitoring metabolic health at baseline and regularly during follow-up, iii) offering lifestyle interventions including regular exercise and healthy diet based on patient preference to optimize motivation, iv) considering first-line psychotherapy for mild-moderate depression and anxiety disorders, v)choosing medications based on medications' and patient's weight gain risk, vi) choosing medications based on acute vs long-term treatment, vii) using effective, tolerated medications, viii) switching to less weight-inducing antipsychotics/antidepressants where possible, ix) using early weight gain as a predictor of further weight gain to inform the timing of intervention/switch options, and x) considering adding metformin or glucagon-like peptide-1 receptor agonists, or topiramate(second-line due to potential adverse cognitive effects) to antipsychotics, or aripiprazole to clozapine or olanzapine.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1249-1269"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study. 使用 FDA 不良事件报告系统评估与抗白细胞介素-6 受体单克隆抗体相关的不良事件:一项真实世界药物警戒研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-25 DOI: 10.1080/14740338.2024.2382227
Jing Hu, Yao Sun, Xiangrong Zuo, Ying Zou

Background: Interleukin-6 (IL-6) monoclonal antibodies are commonly acknowledged for their efficacy in managing coronavirus disease 2019 (COVID-19); however, there remains a paucity of comprehensive studies on their potential adverse effects.

Research design and methods: This is a retrospective pharmacovigilance investigation. We employed FAERS using OpenVigil FDA to detect adverse reactions linked to the interleukin-6 antagonist tocilizumab and sarilumab.

Results: Completely 67,976 reports were identified as 'primary suspected (PS)' adverse events (AEs) for tocilizumab, and 12,560 reports for sarilumab. 109 significant disproportionality preferred terms (PTs) of tocilizumab and 158 PTs of sarilumab were retained. A higher incidence of adverse reactions occurred in females aged 45-64 years, with a higher rate of subsequent hospitalization. Both drugs exhibited adverse reactions consistent with previously reported side effects, such as leukopenia, elevated liver enzymes, and hypercholesterolemia. Additionally, there was a strong correlation with gastrointestinal issues. Unexpected significant adverse events, including diabetes, fluctuations in blood pressure, drug ineffectiveness, malignancies, and disorders of the nervous system, were also observed. Gender and age differences existed in AEs signals related to IL-6RAs.

Conclusion: Our study identified significant new AE signals for interleukin-6 receptor antagonists, potentially supporting clinical monitoring and risk identification for this class of drugs.

背景:白细胞介素-6(IL-6)单克隆抗体在治疗2019年冠状病毒病(COVID-19)方面的疗效已得到普遍认可,但有关其潜在不良反应的全面研究仍然很少:这是一项回顾性药物警戒调查。我们使用OpenVigil FDA的FAERS来检测与白细胞介素-6拮抗剂托珠单抗和沙利单抗相关的不良反应:结果:我们从 FAERS 数据库中收集了 17,037,364 份报告,其中 67,976 份报告被确定为托珠单抗的 "主要疑似 (PS) "不良事件 (AE),12,560 份报告被确定为萨利单抗的 "主要疑似 (PS) "不良事件 (AE)。两种药物引起的不良事件涉及 27 个器官系统。同时保留了所有四种算法中符合沙利单抗标准的109个托西珠单抗重大比例失调首选术语(PT)和158个重大比例失调PT。45-64岁女性的不良反应发生率较高,随后的住院率也较高。两种药物的不良反应与之前报道的副作用一致,如白细胞减少、肝酶升高和高胆固醇血症。此外,还与胃肠道问题密切相关。此外,还观察到意外的重大不良事件,包括糖尿病、血压波动、药物无效、恶性肿瘤和神经系统疾病。与IL-6RAs相关的不良反应信号存在性别和年龄差异:我们的研究发现了白细胞介素-6受体拮抗剂的重要新AE信号,可能有助于对该类药物进行临床监测和风险识别。
{"title":"Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study.","authors":"Jing Hu, Yao Sun, Xiangrong Zuo, Ying Zou","doi":"10.1080/14740338.2024.2382227","DOIUrl":"10.1080/14740338.2024.2382227","url":null,"abstract":"<p><strong>Background: </strong>Interleukin-6 (IL-6) monoclonal antibodies are commonly acknowledged for their efficacy in managing coronavirus disease 2019 (COVID-19); however, there remains a paucity of comprehensive studies on their potential adverse effects.</p><p><strong>Research design and methods: </strong>This is a retrospective pharmacovigilance investigation. We employed FAERS using OpenVigil FDA to detect adverse reactions linked to the interleukin-6 antagonist tocilizumab and sarilumab.</p><p><strong>Results: </strong>Completely 67,976 reports were identified as 'primary suspected (PS)' adverse events (AEs) for tocilizumab, and 12,560 reports for sarilumab. 109 significant disproportionality preferred terms (PTs) of tocilizumab and 158 PTs of sarilumab were retained. A higher incidence of adverse reactions occurred in females aged 45-64 years, with a higher rate of subsequent hospitalization. Both drugs exhibited adverse reactions consistent with previously reported side effects, such as leukopenia, elevated liver enzymes, and hypercholesterolemia. Additionally, there was a strong correlation with gastrointestinal issues. Unexpected significant adverse events, including diabetes, fluctuations in blood pressure, drug ineffectiveness, malignancies, and disorders of the nervous system, were also observed. Gender and age differences existed in AEs signals related to IL-6RAs.</p><p><strong>Conclusion: </strong>Our study identified significant new AE signals for interleukin-6 receptor antagonists, potentially supporting clinical monitoring and risk identification for this class of drugs.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1327-1339"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141758085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database. 伏立康唑诱发的中枢神经系统毒性:基于美国食品药物管理局不良事件报告系统(FAERS)数据库的药物警戒研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-08-19 DOI: 10.1080/14740338.2024.2391492
Juping Yun, Zihe Wang, Wei Liu

Background: This study aims to evaluate the relationship between voriconazole (VRC) and central nervous system (CNS) toxicity based on the real world data.

Research design and methods: The reports of FAERS from January 2004 to March 2022 were included in our study. The CNS toxicity events were identified by using Medical Dictionary for Regulatory Activities terms. Reporting odds ratios corresponding to 95% confidence intervals were employed to quantify the signals of VRC-associated CNS events.

Results: The overall RORs (95%CI) for psychiatric disorders, nervous system disorders, and eye disorders were 1.84 (1.70, 2.00), 1.09 (1.01, 1.18), and 3.84 (3.48, 4.23), respectively (p < 0.05). The median time to the CNS events of VRC was 1(IQR 0-5) day. Top six signals were macular opacity, chloropsia, scintillating scotoma, toxic optic neuropathy, corneal bleeding, and dyschromatopsia, all of them grouped as eye disorders. Compared with itraconazole, fluconazole, posaconazole, and isavuconazole, VRC shows significant relationship and higher incidence rate of psychiatric disorders, nervous system disorders, and eye disorders, respectively (p < 0.05).

Conclusions: VRC was significantly associated with the CNS toxicity. Dosing adjustment, model-based individualized treatment project, and the therapeutic drug monitoring-guided individualized medication regime could be good strategies for efficacy improvement and the adverse events of reducing of VRC.

研究背景本研究旨在根据实际数据评估伏立康唑(Voriconazole,VRC)与中枢神经系统(CNS)毒性之间的关系:我们的研究纳入了2004年1月至2022年3月的FAERS报告。中枢神经系统毒性事件通过使用《监管活动医学词典》中的术语进行识别。采用与95%置信区间相对应的报告几率比来量化VRC相关中枢神经系统事件的信号:结果:精神疾病、神经系统疾病和眼部疾病的总体几率比(95%置信区间)分别为 1.84(1.70,2.00)、1.09(1.01,1.18)和 3.84(3.48,4.23)(P<0.05)。发生 VRC 中枢神经系统事件的中位时间为 1 天(IQR 0-5 天)。前六位信号分别为黄斑翳、氯斑、闪烁性视网膜病变、中毒性视神经病变、角膜出血和色觉障碍,均属于眼部疾病。与伊曲康唑、氟康唑、泊沙康唑和异武康唑相比,VRC 与精神疾病、神经系统疾病和眼部疾病有显著关系,且发病率更高(P<0.05):结论:VRC 与中枢神经系统毒性密切相关。调整剂量、基于模型的个体化治疗项目和治疗药物监测指导下的个体化用药方案可能是提高 VRC 疗效和减少不良反应的良策。
{"title":"Voriconazole-induced central nervous system toxicity: a pharmacovigilance study based on FDA adverse event reporting system (FAERS) database.","authors":"Juping Yun, Zihe Wang, Wei Liu","doi":"10.1080/14740338.2024.2391492","DOIUrl":"10.1080/14740338.2024.2391492","url":null,"abstract":"<p><strong>Background: </strong>This study aims to evaluate the relationship between voriconazole (VRC) and central nervous system (CNS) toxicity based on the real world data.</p><p><strong>Research design and methods: </strong>The reports of FAERS from January 2004 to March 2022 were included in our study. The CNS toxicity events were identified by using Medical Dictionary for Regulatory Activities terms. Reporting odds ratios corresponding to 95% confidence intervals were employed to quantify the signals of VRC-associated CNS events.</p><p><strong>Results: </strong>The overall RORs (95%CI) for psychiatric disorders, nervous system disorders, and eye disorders were 1.84 (1.70, 2.00), 1.09 (1.01, 1.18), and 3.84 (3.48, 4.23), respectively (p < 0.05). The median time to the CNS events of VRC was 1(IQR 0-5) day. Top six signals were macular opacity, chloropsia, scintillating scotoma, toxic optic neuropathy, corneal bleeding, and dyschromatopsia, all of them grouped as eye disorders. Compared with itraconazole, fluconazole, posaconazole, and isavuconazole, VRC shows significant relationship and higher incidence rate of psychiatric disorders, nervous system disorders, and eye disorders, respectively (p < 0.05).</p><p><strong>Conclusions: </strong>VRC was significantly associated with the CNS toxicity. Dosing adjustment, model-based individualized treatment project, and the therapeutic drug monitoring-guided individualized medication regime could be good strategies for efficacy improvement and the adverse events of reducing of VRC.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1309-1316"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS. 新型心血管药物 vericiguat 的不良事件评估:基于 FAERS 的真实世界药物警戒研究。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-19 DOI: 10.1080/14740338.2024.2382226
Jin Rao, Xiangyu Chen, Yudi Liu, Xuefu Wang, Pengchao Cheng, Zhinong Wang

Background: This study aims to analyze the adverse event reports (AERs) to vericiguat using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and provide evidence for the clinical use.

Methods: AERs due to vericiguat from 2021Q1 to 2024Q1 identified as the primary suspect were screened, with duplicate reports subsequently eliminated. Various quantitative signal detection methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were then employed for data mining and analysis. Signal strength is represented by the 95% confidence interval, information component (IC), and empirical Bayesian geometric mean (EBGM).

Results: A total of 617 vericiguat-related AERs were identified. Strong signals were observed in 21 system organ classes. Furthermore, the most frequently reported preferred terms (PT) was hypotension (n = 86, ROR 25.92, PRR 24.11, IC 4.59, EBGM 24.07), followed by dizziness (n = 52, ROR 6.44, PRR 6.20, IC 2.63, EBGM 6.20), malaise (n = 25, ROR 3.59, PRR 3.54, IC 1.82, EBGM 3.54), blood pressure decreased (n = 23, ROR 20.00, PRR 19.64, IC 4.29, EBGM 19.61), and anemia (n = 21, ROR 6.67, PRR 6.57, IC 2.72, EBGM 6.57).

Conclusions: This study extended the adverse reactions documented in the FDA instruction and provided supplementary evidence regarding the clinical safety of vericiguat.

研究背景本研究旨在利用美国食品和药物管理局不良事件报告系统(FAERS)的数据分析韦立克(vericiguat)的不良事件报告(AERs),并为临床应用提供证据:筛选了2021Q1至2024Q1期间被确定为主要疑似药物的韦立克AER,随后剔除了重复报告。然后采用各种定量信号检测方法,包括报告几率比(ROR)、比例报告比(PRR)、贝叶斯置信度传播神经网络和多项目伽马泊松收缩器,进行数据挖掘和分析。信号强度用 95% 置信区间、信息成分(IC)和经验贝叶斯几何平均数(EBGM)表示:结果:共发现了 617 个与 vericiguat 相关的 AER。在 21 个系统器官类别中观察到强烈信号。此外,最常报告的首选术语(PT)是低血压(n = 86,ROR 25.92,PRR 24.11,IC 4.59,EBGM 24.07),其次是头晕(n = 52,ROR 6.44,PRR 6.20,IC 2.63,EBGM 6.20)、乏力(n = 25,ROR 3.59,PRR 3.54,IC 1.82,EBGM 3.54)、血压下降(n = 23,ROR 20.00,PRR 19.64,IC 4.29,EBGM 19.61)和贫血(n = 21,ROR 6.67,PRR 6.57,IC 2.72,EBGM 6.57):本研究扩展了 FDA 说明书中记录的不良反应,为 vericiguat 的临床安全性提供了补充证据。
{"title":"Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.","authors":"Jin Rao, Xiangyu Chen, Yudi Liu, Xuefu Wang, Pengchao Cheng, Zhinong Wang","doi":"10.1080/14740338.2024.2382226","DOIUrl":"10.1080/14740338.2024.2382226","url":null,"abstract":"<p><strong>Background: </strong>This study aims to analyze the adverse event reports (AERs) to vericiguat using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and provide evidence for the clinical use.</p><p><strong>Methods: </strong>AERs due to vericiguat from 2021Q1 to 2024Q1 identified as the primary suspect were screened, with duplicate reports subsequently eliminated. Various quantitative signal detection methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were then employed for data mining and analysis. Signal strength is represented by the 95% confidence interval, information component (IC), and empirical Bayesian geometric mean (EBGM).</p><p><strong>Results: </strong>A total of 617 vericiguat-related AERs were identified. Strong signals were observed in 21 system organ classes. Furthermore, the most frequently reported preferred terms (PT) was hypotension (<i>n</i> = 86, ROR 25.92, PRR 24.11, IC 4.59, EBGM 24.07), followed by dizziness (<i>n</i> = 52, ROR 6.44, PRR 6.20, IC 2.63, EBGM 6.20), malaise (<i>n</i> = 25, ROR 3.59, PRR 3.54, IC 1.82, EBGM 3.54), blood pressure decreased (<i>n</i> = 23, ROR 20.00, PRR 19.64, IC 4.29, EBGM 19.61), and anemia (<i>n</i> = 21, ROR 6.67, PRR 6.57, IC 2.72, EBGM 6.57).</p><p><strong>Conclusions: </strong>This study extended the adverse reactions documented in the FDA instruction and provided supplementary evidence regarding the clinical safety of vericiguat.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1317-1325"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety assessment of sildenafil use in neonates: a real-world data analysis based on the FDA adverse event reporting system (FAERS). 新生儿使用西地那非的安全性评估:基于 FDA 不良事件报告系统 (FAERS) 的真实世界数据分析。
IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-10-01 Epub Date: 2024-07-22 DOI: 10.1080/14740338.2024.2383710
Bo Wang, Jia Zhang, Rui Cheng

Background: The safety of neonatal sildenafil use remains uncertain. This study aimed to investigate adverse events (AEs) associated with sildenafil use in neonates.

Research design and methods: We collected data on AEs associated with sildenafil use in neonates from the US Food and Drug Administration Adverse Event Reporting System database, spanning from its inception of the database in 2004 to 2023. Disproportionality measures were employed to analyze the correlation between AEs and sildenafil.

Results: Sildenafil was identified as the primary suspect drug in 75 AE reports, involving 214 AEs. Three system organ classes, namely, eye disorders, hepatobiliary disorders, and vascular disorders were associated with sildenafil use. Six preferred terms, namely, flushing, retinopathy of prematurity, hyperbilirubinemia, pulmonary hemorrhage, hypotension, and diarrhea were associated with sildenafil use. Notably, hyperbilirubinemia and pulmonary hemorrhage were previously unreported AEs associated with sildenafil use.

Conclusion: The results highlight the ongoing uncertainty surrounding the safety of neonatal sildenafil use and provide vital support for risk monitoring and identification in neonates receiving sildenafil. Additionally, the study underscores the need for continuous safety surveillance in neonates treated with sildenafil and suggests further exploration of the precise causal relationships between AEs and sildenafil.

背景:新生儿使用西地那非的安全性仍不确定。本研究旨在调查与新生儿使用西地那非相关的不良事件(AEs):我们从美国食品和药物管理局不良事件报告系统数据库中收集了与新生儿使用西地那非相关的AEs数据,时间跨度为2004年数据库建立之初至2023年。结果显示,西地那非被确定为导致新生儿AE的主要药物:在75例AE报告中,西地那非被确定为主要可疑药物,涉及214例AE。三个系统器官类别,即眼部疾病、肝胆疾病和血管疾病与使用西地那非有关。六个首选术语,即潮红、早产儿视网膜病变、高胆红素血症、肺出血、低血压和腹泻与使用西地那非有关。值得注意的是,高胆红素血症和肺出血是以前未报告过的与使用西地那非有关的AE:研究结果凸显了新生儿使用西地那非安全性的不确定性,为新生儿使用西地那非的风险监测和识别提供了重要支持。此外,该研究还强调了对接受西地那非治疗的新生儿进行持续安全监测的必要性,并建议进一步探讨AE与西地那非之间的确切因果关系。
{"title":"Safety assessment of sildenafil use in neonates: a real-world data analysis based on the FDA adverse event reporting system (FAERS).","authors":"Bo Wang, Jia Zhang, Rui Cheng","doi":"10.1080/14740338.2024.2383710","DOIUrl":"10.1080/14740338.2024.2383710","url":null,"abstract":"<p><strong>Background: </strong>The safety of neonatal sildenafil use remains uncertain. This study aimed to investigate adverse events (AEs) associated with sildenafil use in neonates.</p><p><strong>Research design and methods: </strong>We collected data on AEs associated with sildenafil use in neonates from the US Food and Drug Administration Adverse Event Reporting System database, spanning from its inception of the database in 2004 to 2023. Disproportionality measures were employed to analyze the correlation between AEs and sildenafil.</p><p><strong>Results: </strong>Sildenafil was identified as the primary suspect drug in 75 AE reports, involving 214 AEs. Three system organ classes, namely, eye disorders, hepatobiliary disorders, and vascular disorders were associated with sildenafil use. Six preferred terms, namely, flushing, retinopathy of prematurity, hyperbilirubinemia, pulmonary hemorrhage, hypotension, and diarrhea were associated with sildenafil use. Notably, hyperbilirubinemia and pulmonary hemorrhage were previously unreported AEs associated with sildenafil use.</p><p><strong>Conclusion: </strong>The results highlight the ongoing uncertainty surrounding the safety of neonatal sildenafil use and provide vital support for risk monitoring and identification in neonates receiving sildenafil. Additionally, the study underscores the need for continuous safety surveillance in neonates treated with sildenafil and suggests further exploration of the precise causal relationships between AEs and sildenafil.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1341-1346"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Expert Opinion on Drug Safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1